Insider Buying: GSK (LON:GSK) Insider Buys 7 Shares of Stock

Key Points

• GSK insider Emma Walmsley purchased 7 shares of the company's stock on October 9th for a total of £114.87, with the shares bought at an average price of GBX 1,641 each.
• Following recent trades, GSK shares opened at GBX 1,625, reflecting a 0.9% decline on the previous trading day.
• Analysts have a consensus rating of "Hold" on GSK stock, with target prices ranging from GBX 1,450 to GBX 2,100.

GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley bought 7 shares of the company's stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average price of GBX 1,641 per share, for a total transaction of £114.87.

Emma Walmsley also recently made the following trade(s):

• On Tuesday, September 9th, Emma Walmsley acquired 9 shares of GSK stock. The shares were bought at an average price of GBX 1,486 per share, for a total transaction of £133.74.
• On Monday, August 11th, Emma Walmsley acquired 9 shares of GSK stock. The shares were bought at an average price of GBX 1,408 per share, for a total transaction of £126.72.

GSK Stock Down 0.9%

Shares of LON GSK traded down GBX 15 during trading on Friday, hitting GBX 1,625. 6,694,230 shares of the company traded hands, compared to its average volume of 12,062,612. The business's fifty day moving average is GBX 1,483.79 and its 200 day moving average is GBX 1,438.37. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,684.50. The firm has a market capitalization of £65.40 billion, a price-to-earnings ratio of 1,964.93, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 1,450 target price on shares of GSK in a report on Thursday, July 31st. Berenberg Bank restated a "hold" rating and issued a GBX 1,600 target price on shares of GSK in a report on Friday, July 18th. JPMorgan Chase & Co. restated an "under review" rating on shares of GSK in a report on Friday, October 3rd. Finally, Shore Capital restated a "buy" rating and issued a GBX 2,100 target price on shares of GSK in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.